On Jun. 7, 2021, OraSure Technologies announced that it had received Emergency Use Authorization (EUA) from the FDA for its COVID-19 rapid antigen tests, which the Company is branding as InteliSwabﾙ. These tests detect active COVID-19 infection.

The FDA has authorized the InteliSwabﾙ COVID-19 Rapid Test for Over-the-Counter (OTC) use without a prescription. FDA also authorized the InteliSwabﾙ COVID-19 Rapid Test Pro for professional use in point of care (POC) CLIA-waived settings, and the InteliSwabﾙ COVID-19 Rapid Test Rx for Prescription Home Use.